ZA200710699B - Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor - Google Patents
Piperazine-piperidine antagonists and agonists of the 5-HT1A receptorInfo
- Publication number
- ZA200710699B ZA200710699B ZA200710699A ZA200710699A ZA200710699B ZA 200710699 B ZA200710699 B ZA 200710699B ZA 200710699 A ZA200710699 A ZA 200710699A ZA 200710699 A ZA200710699 A ZA 200710699A ZA 200710699 B ZA200710699 B ZA 200710699B
- Authority
- ZA
- South Africa
- Prior art keywords
- agonists
- piperazine
- ht1a receptor
- piperidine antagonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68946905P | 2005-06-10 | 2005-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200710699B true ZA200710699B (en) | 2009-05-27 |
Family
ID=37530084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200710699A ZA200710699B (en) | 2005-06-10 | 2007-12-07 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor |
Country Status (20)
Country | Link |
---|---|
US (1) | US7671056B2 (es) |
EP (1) | EP1888559A2 (es) |
JP (1) | JP2008543782A (es) |
KR (1) | KR20080021134A (es) |
CN (1) | CN101243073A (es) |
AR (1) | AR055059A1 (es) |
AU (1) | AU2006257874A1 (es) |
BR (1) | BRPI0613491A2 (es) |
CA (1) | CA2611711A1 (es) |
CR (1) | CR9560A (es) |
EC (1) | ECSP088094A (es) |
GT (1) | GT200600255A (es) |
IL (1) | IL187972A0 (es) |
MX (1) | MX2007015678A (es) |
NO (1) | NO20076344L (es) |
PE (1) | PE20070069A1 (es) |
RU (1) | RU2007146543A (es) |
TW (1) | TW200800959A (es) |
WO (1) | WO2006135839A2 (es) |
ZA (1) | ZA200710699B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808730A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Process for synthesizing piperazine-piperidine compounds |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
US20080032965A1 (en) * | 2006-06-09 | 2008-02-07 | Hirst Warren D | Method for enhancing cognitive function |
TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
US20080199518A1 (en) * | 2006-11-28 | 2008-08-21 | Wyeth | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution |
AR065376A1 (es) * | 2007-02-16 | 2009-06-03 | Wyeth Corp | Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina - piperidina del receptor 5 ht1a que tienen disolucion instestinal mejorada |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
CN101797223B (zh) * | 2009-02-06 | 2012-05-23 | 上海交通大学医学院 | 石杉碱甲眼用制剂及其应用 |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
PL3061821T3 (pl) * | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
BR112021005802B1 (pt) | 2018-09-28 | 2022-02-15 | Karuna Therapeutics, Inc | Composição farmacêutica oral |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2908952C3 (de) | 1979-03-07 | 1981-12-03 | Gerhard Hug Gmbh, 7801 Umkirch | Drainagevorrichtung |
US4665183A (en) | 1985-12-20 | 1987-05-12 | American Home Products Corp. | Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments |
US4624954A (en) | 1985-12-20 | 1986-11-25 | American Home Products Corporation | 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments |
US5219857A (en) | 1986-10-16 | 1993-06-15 | American Cyanamid Company | Method of treating cognitive and related neural behavioral problems |
US4904658A (en) | 1988-04-15 | 1990-02-27 | American Cyanamid Company | Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones |
US5260331A (en) | 1989-01-02 | 1993-11-09 | John Wyeth & Brother Limited | Composition for treating depression with (S- or O-heteroaryl)alkyl amines |
US5422355A (en) | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
ES2130135T3 (es) | 1990-01-11 | 1999-07-01 | Upjohn Co | Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central. |
AU645681B2 (en) | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9125615D0 (en) | 1991-12-02 | 1992-01-29 | Wyeth John & Brother Ltd | Amines |
ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
DE69323212T2 (de) | 1992-12-17 | 1999-05-27 | Pfizer | Pyrazole mit crf antagonistischer aktivität |
DK0674641T3 (da) | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidiner som CRF-antagonister |
RU2130453C1 (ru) | 1992-12-17 | 1999-05-20 | Пфайзер Инк. | Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
WO1997045403A1 (en) | 1996-05-31 | 1997-12-04 | Pharmacia & Upjohn Company | Aryl substituted cyclic amines as selective dopamine d3 ligands |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
HUP0101280A3 (en) | 1998-02-18 | 2003-02-28 | Neurosearch As | Positive ampa receptor modulator compounds and their use |
US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
SE9804126D0 (sv) | 1998-11-27 | 1998-11-27 | Astra Ab | New pharmaceutical composition |
JP2002534411A (ja) | 1999-01-07 | 2002-10-15 | ワイス | 鬱病の処置のためのアリールピペラジニル−シクロヘキシルインドール誘導体 |
US6313126B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
DE60112064T2 (de) | 2000-04-10 | 2006-06-01 | Pfizer Products Inc., Groton | Benzoamid-piperidin verbindungen als substanz p-antagonisten |
DE10043659A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1203584A1 (en) | 2000-10-13 | 2002-05-08 | M.D.M. S.r.l. | Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
IL156268A0 (en) | 2000-12-13 | 2004-01-04 | Wyeth Corp | Heterocyclic sulfonamide inhibitors of beta amyloid production |
WO2002088145A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS |
WO2002088132A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists |
WO2003010169A1 (en) | 2001-07-25 | 2003-02-06 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene |
US20030060513A1 (en) | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
DE10217006A1 (de) | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
CA2484936A1 (en) | 2002-05-08 | 2004-05-21 | Neurogen Corporation | Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200401641A (en) | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
KR20050040921A (ko) | 2002-08-15 | 2005-05-03 | 와이어쓰 | 체온조절 기능장애 치료를 위한 5HT2a 수용체의 항진제 |
US7153849B2 (en) | 2002-09-12 | 2006-12-26 | Wyeth | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
WO2004045718A2 (en) | 2002-11-20 | 2004-06-03 | Cypress Bioscience, Inc. | Treatment of cognitive dysfunctions' |
US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
US7276603B2 (en) | 2003-05-02 | 2007-10-02 | Wyeth | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use |
US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
WO2005012311A1 (en) | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
ATE425752T1 (de) | 2003-12-02 | 2009-04-15 | Pharmaneuroboost N V | Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen |
MY179926A (en) | 2003-12-08 | 2020-11-19 | Wyeth Corp | Process for the preparation of tubulin inhibitors |
WO2005082372A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
US20050197356A1 (en) | 2004-03-02 | 2005-09-08 | Wyeth | Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents |
EP1720886A1 (en) | 2004-03-02 | 2006-11-15 | Wyeth | Macrolides and methods for producing same |
US20050215561A1 (en) | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
TWI391387B (zh) | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
JP2008503460A (ja) | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン |
NZ552031A (en) | 2004-06-16 | 2009-06-26 | Wyeth Corp | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
EP1799264A2 (en) | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
MX2007009923A (es) | 2005-02-15 | 2008-03-04 | Jazz Pharmaceuticals | Forma farmaceutica y metodo para liberacion sostenida de un compuesto de pirazina sustituido. |
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
JP4796927B2 (ja) | 2005-11-28 | 2011-10-19 | 株式会社豊田中央研究所 | クロック信号出力回路 |
TW200808740A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
US20080032965A1 (en) | 2006-06-09 | 2008-02-07 | Hirst Warren D | Method for enhancing cognitive function |
TW200808730A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | Process for synthesizing piperazine-piperidine compounds |
TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
US20080199518A1 (en) | 2006-11-28 | 2008-08-21 | Wyeth | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution |
-
2006
- 2006-06-08 TW TW095120358A patent/TW200800959A/zh unknown
- 2006-06-09 BR BRPI0613491-2A patent/BRPI0613491A2/pt not_active Application Discontinuation
- 2006-06-09 AU AU2006257874A patent/AU2006257874A1/en not_active Abandoned
- 2006-06-09 EP EP06772861A patent/EP1888559A2/en not_active Withdrawn
- 2006-06-09 RU RU2007146543/04A patent/RU2007146543A/ru not_active Application Discontinuation
- 2006-06-09 KR KR1020087000800A patent/KR20080021134A/ko not_active Application Discontinuation
- 2006-06-09 GT GT200600255A patent/GT200600255A/es unknown
- 2006-06-09 US US11/450,942 patent/US7671056B2/en not_active Expired - Fee Related
- 2006-06-09 PE PE2006000646A patent/PE20070069A1/es not_active Application Discontinuation
- 2006-06-09 CA CA002611711A patent/CA2611711A1/en not_active Abandoned
- 2006-06-09 WO PCT/US2006/022719 patent/WO2006135839A2/en active Application Filing
- 2006-06-09 CN CNA2006800292484A patent/CN101243073A/zh active Pending
- 2006-06-09 JP JP2008516005A patent/JP2008543782A/ja active Pending
- 2006-06-09 MX MX2007015678A patent/MX2007015678A/es not_active Application Discontinuation
- 2006-06-12 AR ARP060102469A patent/AR055059A1/es unknown
-
2007
- 2007-12-05 CR CR9560A patent/CR9560A/es not_active Application Discontinuation
- 2007-12-06 IL IL187972A patent/IL187972A0/en unknown
- 2007-12-07 ZA ZA200710699A patent/ZA200710699B/xx unknown
- 2007-12-11 NO NO20076344A patent/NO20076344L/no not_active Application Discontinuation
-
2008
- 2008-01-10 EC EC2008008094A patent/ECSP088094A/es unknown
Also Published As
Publication number | Publication date |
---|---|
GT200600255A (es) | 2007-07-19 |
NO20076344L (no) | 2008-02-27 |
AR055059A1 (es) | 2007-08-01 |
JP2008543782A (ja) | 2008-12-04 |
US7671056B2 (en) | 2010-03-02 |
TW200800959A (en) | 2008-01-01 |
CN101243073A (zh) | 2008-08-13 |
CA2611711A1 (en) | 2006-12-21 |
PE20070069A1 (es) | 2007-03-15 |
BRPI0613491A2 (pt) | 2011-01-11 |
WO2006135839A2 (en) | 2006-12-21 |
ECSP088094A (es) | 2008-02-20 |
CR9560A (es) | 2008-02-20 |
EP1888559A2 (en) | 2008-02-20 |
WO2006135839A3 (en) | 2007-11-22 |
RU2007146543A (ru) | 2009-07-20 |
AU2006257874A1 (en) | 2006-12-21 |
US20070027160A1 (en) | 2007-02-01 |
KR20080021134A (ko) | 2008-03-06 |
MX2007015678A (es) | 2008-02-20 |
IL187972A0 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200710699B (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | |
TWI318206B (en) | Histamine-3 receptor antagonists | |
IL186601A0 (en) | Npy antagonists, preparation and use | |
ZA200803811B (en) | Neuropolin antagonists | |
IL192426A0 (en) | Prokineticin 2 receptor antagonists | |
IL179462A0 (en) | Use of the receptor gpr86 | |
IL225521A0 (en) | 1trpv antagonists and their uses | |
ZA200807382B (en) | Novel Dual Action Receptors Antagonists (DARA) at the ati and eta receptors | |
IL192424A0 (en) | Prokineticin 1 receptor antagonists | |
IL186908A0 (en) | Trpv1 agonist compounds and methods for making and using the same | |
GB0611154D0 (en) | Novel receptor antagonists and their methods of use | |
ZA200709147B (en) | Pyrimidindione derivatives as prokineticin 2 receptor antagonists | |
IL205608A0 (en) | Triazole -substituted arylamide derivatives and their use as p2x3 and/or p2x2/3purinergic receptor antagonists | |
EP1928496A4 (en) | C / CLP ANTAGONISTS AND METHOD OF USE | |
EP1962635A4 (en) | LOAD REDUCTION FOR SHOULDER AND USE THEREOF | |
ZA200900303B (en) | Cinnamoyl-piperazine derivatives and their use as par-i antagonists | |
IL178461A0 (en) | Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | |
ZA200710169B (en) | Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists | |
HK1084441A1 (en) | Orientable probe | |
EP1838730A4 (en) | PAN-HER ANTAGONISTS AND METHODS OF USE | |
IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
HK1146065A1 (en) | Nlrr-1 antagonists and uses thereof nlrr-1 | |
GB0503111D0 (en) | Receptor agonists and their use | |
ZA200805851B (en) | Stress-reducer for shoulder and the use thereof | |
GB0604234D0 (en) | Novel receptor antagonists and their methods of use |